Searching Address

Request Samples*

All fields are required.

I authorize Paratek Pharmaceuticals, Inc. (“Paratek”), its affiliates, and companies working with Paratek to contact me by email, telephone, and electronic message (including autodialed and prerecorded calls and messages) for marketing purposes, such as to provide me with information, offers, and promotions regarding topics that may be of interest, Paratek products and programs, to conduct market research or surveys, and to use my information to develop future products, services, and programs. I understand that I may choose to no longer receive further communications from Paratek by following the unsubscribe instructions on the communication or by contacting info@xhance.com. Please visit https://www.paratekpharma.com/privacy-policy to view our Privacy Policy.

{{ matches.length }} records found.

Reset Search

Please confirm your address:

  • {{ match.address1 }}

Show more

*In compliance with applicable laws and regulations.

Submission complete

Thank you for your submission. Your request has been received and is being processed.

Explore More

Find additional information for patients and healthcare professionals

Go to Resources

See the results of the XHANCE clinical trials

Review Results

+
References
  1. Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2024.
  2. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.
  3. Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.e5.
INDICATIONS
XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

  • Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa.  Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
  • Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
  • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate.  Discontinue XHANCE if such reactions occur.
  • Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex).  Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
  • Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals.  If such changes occur, discontinue XHANCE slowly.
  • Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

  • Chronic rhinosinusitis without nasal polyps:  The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
  • Chronic rhinosinusitis with nasal polyps:  The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment.  Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.